Post-CAR-T-cell infusion factors and risk for first infection within 28 days using Cox proportional hazards regression
| Post-CAR–T-cell infusion variables . | Unadjusted HR* (95% CI) . | P . |
|---|---|---|
| CAR–T-cell dose level, cells per kg | ||
| 2 × 107 vs 2 × 105 | 3.19 (1.07-9.51) | .038 |
| 2 × 107 vs 2 × 106 | 3.15 (1.24-8.01) | .016 |
| ANC < 500 cells per mm3 on day of infection | 2.04 (0.85-4.89) | .11 |
| CRS grade | ||
| 0 vs 1-3 vs 4-5† | 3.38 (1.99-5.73) | <.001 |
| Neurotoxicity grade | ||
| 0 vs 1-2 vs 3-5‡ | 1.76 (1.11-2.78) | .015 |
| Tocilizumab use§ | 3.45 (1.23-9.67) | .019 |
| Corticosteroid use§ | 1.50 (0.43-5.23) | .5 |
| ICU admission | 4.35 (1.78-10.65) | .001 |
| Post-CAR–T-cell infusion variables . | Unadjusted HR* (95% CI) . | P . |
|---|---|---|
| CAR–T-cell dose level, cells per kg | ||
| 2 × 107 vs 2 × 105 | 3.19 (1.07-9.51) | .038 |
| 2 × 107 vs 2 × 106 | 3.15 (1.24-8.01) | .016 |
| ANC < 500 cells per mm3 on day of infection | 2.04 (0.85-4.89) | .11 |
| CRS grade | ||
| 0 vs 1-3 vs 4-5† | 3.38 (1.99-5.73) | <.001 |
| Neurotoxicity grade | ||
| 0 vs 1-2 vs 3-5‡ | 1.76 (1.11-2.78) | .015 |
| Tocilizumab use§ | 3.45 (1.23-9.67) | .019 |
| Corticosteroid use§ | 1.50 (0.43-5.23) | .5 |
| ICU admission | 4.35 (1.78-10.65) | .001 |
HR, hazard ratio.
Data shown are from the univariate model only. CRS was the only significant variable in a stepwise multivariable model. Other baseline characteristics with P < .1 but not significant at the P < .05 level included prior antitumor treatment regimens ≥4. There was collinearity between CAR–T-cell dose level, CRS grade, neurotoxicity grade, tocilizumab use, corticosteroid use, and ICU admission.
For each increase in CRS severity category from 0 (none) to grades 1-3 to grades 4-5, there was a 3.38 increase in the hazard of infection.
For each increase in neurotoxicity severity category from 0 (none) to grades 1-2 to grades 3-5, there was a 1.76 increase in the hazard of infection.
These were analyzed as dichotomous variables (ie, yes vs no).